Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
OpenAI Restricts Astra AI Over Cyberattack Risks 
 - EconoTimes)
RANCHO CORDOVA, Calif., Feb. 28, 2018 -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL) a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that Phil Coelho, chief technology officer of ThermoGenesis Corp., Cesca’s device division, will be presenting at the 8th Spring Meeting of the International Society for BioProcess Technology (ISBiotech). ISBiotech is being held March 5-7, 2018 at the Hilton Norfolk The Main Hotel in Norfolk, Virginia.
Mr. Coelho’s presentation, “Automated, Closed System Manufacturing of CAR-T Cells,” is scheduled to take place on Wednesday, March 7 from 1:30-2:15pm EST.
For more information about the ISBiotech Spring Meeting, go to: www.isbiotech.org
About Cesca Therapeutics Inc.
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress platform that addresses the critical unmet need for better cellular manufacturing and controls (CMC) for the emerging CAR-T immunotherapy market. Cesca is an affiliated company of China-based Boyalife Group.
Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
[email protected]
Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
[email protected]
